ATE273712T1 - Methode zur inaktivierung von proteinen der ras- unterfamilie und verbindungen dafuer - Google Patents
Methode zur inaktivierung von proteinen der ras- unterfamilie und verbindungen dafuerInfo
- Publication number
- ATE273712T1 ATE273712T1 AT97902278T AT97902278T ATE273712T1 AT E273712 T1 ATE273712 T1 AT E273712T1 AT 97902278 T AT97902278 T AT 97902278T AT 97902278 T AT97902278 T AT 97902278T AT E273712 T1 ATE273712 T1 AT E273712T1
- Authority
- AT
- Austria
- Prior art keywords
- inactivation
- ras
- compounds therefor
- ras subfamily
- subfamily proteins
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 230000002779 inactivation Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- 230000002588 toxic effect Effects 0.000 abstract 2
- 239000003053 toxin Substances 0.000 abstract 2
- 231100000765 toxin Toxicity 0.000 abstract 2
- 241000193465 Paeniclostridium sordellii Species 0.000 abstract 1
- 102000052575 Proto-Oncogene Human genes 0.000 abstract 1
- 108700020978 Proto-Oncogene Proteins 0.000 abstract 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 abstract 1
- 239000004473 Threonine Substances 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000003197 catalytic effect Effects 0.000 abstract 1
- 239000002596 immunotoxin Substances 0.000 abstract 1
- 231100000608 immunotoxin Toxicity 0.000 abstract 1
- 229940051026 immunotoxin Drugs 0.000 abstract 1
- 230000002637 immunotoxin Effects 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/825—Bacteria
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Electrotherapy Devices (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP96101469 | 1996-02-02 | ||
| PCT/EP1997/000426 WO1997027871A1 (en) | 1996-02-02 | 1997-01-31 | Method of inactivation of ras subfamily proteins and agents therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE273712T1 true ATE273712T1 (de) | 2004-09-15 |
Family
ID=8222454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97902278T ATE273712T1 (de) | 1996-02-02 | 1997-01-31 | Methode zur inaktivierung von proteinen der ras- unterfamilie und verbindungen dafuer |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6849715B2 (de) |
| EP (1) | EP0877622B1 (de) |
| AT (1) | ATE273712T1 (de) |
| AU (1) | AU1598297A (de) |
| DE (1) | DE69730313T2 (de) |
| DK (1) | DK0877622T3 (de) |
| ES (1) | ES2227667T3 (de) |
| PT (1) | PT877622E (de) |
| WO (1) | WO1997027871A1 (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8007782B2 (en) * | 2003-10-22 | 2011-08-30 | The Johns Hopkins University | Combination bacteriolytic therapy for the treatment of tumors |
| WO2005039491A2 (en) * | 2003-10-22 | 2005-05-06 | The John Hopkins University | Certain improved combination bacteriolytic therapy for the treatment of tumors |
| US12415995B2 (en) | 2014-08-01 | 2025-09-16 | Northwestern University | Bacterial toxins and uses thereof as Ras specific proteases for treating cell proliferation diseases and disorders |
| US10829752B2 (en) | 2014-08-01 | 2020-11-10 | Northwestern University | Bacterial toxins and uses thereof as Ras specific proteases for treating cell proliferation diseases and disorders |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2694296B1 (fr) * | 1992-07-30 | 1994-09-02 | Rhone Poulenc Rorer Sa | Peptides inhibant l'activité des protéines ras, préparation et utilisation. |
| WO1994022476A1 (en) * | 1993-03-29 | 1994-10-13 | Pfizer Inc. | Multicomponent clostridial vaccines using saponin adjuvants |
-
1997
- 1997-01-31 EP EP97902278A patent/EP0877622B1/de not_active Expired - Lifetime
- 1997-01-31 DK DK97902278T patent/DK0877622T3/da active
- 1997-01-31 AT AT97902278T patent/ATE273712T1/de not_active IP Right Cessation
- 1997-01-31 DE DE69730313T patent/DE69730313T2/de not_active Expired - Lifetime
- 1997-01-31 WO PCT/EP1997/000426 patent/WO1997027871A1/en not_active Ceased
- 1997-01-31 ES ES97902278T patent/ES2227667T3/es not_active Expired - Lifetime
- 1997-01-31 AU AU15982/97A patent/AU1598297A/en not_active Abandoned
- 1997-01-31 PT PT97902278T patent/PT877622E/pt unknown
-
1998
- 1998-07-31 US US09/126,816 patent/US6849715B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP0877622B1 (de) | 2004-08-18 |
| US6849715B2 (en) | 2005-02-01 |
| ES2227667T3 (es) | 2005-04-01 |
| US20030103987A1 (en) | 2003-06-05 |
| DE69730313T2 (de) | 2005-09-01 |
| EP0877622A1 (de) | 1998-11-18 |
| WO1997027871A1 (en) | 1997-08-07 |
| AU1598297A (en) | 1997-08-22 |
| DE69730313D1 (de) | 2004-09-23 |
| PT877622E (pt) | 2005-01-31 |
| DK0877622T3 (da) | 2004-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Violand et al. | Mechanism of the urokinase-catalyzed activation of human plasminogen. | |
| ATE279181T1 (de) | Verwendung von 5ht-6 antagonisten zur behandlung adhd | |
| DE69421778D1 (de) | Verwendung von wirksamen Mengen von aktiven Stoffen zur Behandlung von Mischhaut | |
| DE69328550D1 (de) | Verwendung von fulleren-derivaten in diagnostischen und/oder therapeutischen mitteln | |
| ATE319823T1 (de) | Bmp-12, bmp-13 und diese enthaltende sehne- induzierende zusammensetzungen | |
| DE69201792D1 (de) | System und kontinuierliches verfahren zur biokatalytischen entschwefelung von schwefelhaltigen heterozyklischen molekülen. | |
| ATE241358T1 (de) | Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen | |
| DK0653911T3 (da) | Fremgangsmåder til inaktivering af bakterier i blodpræparater med 8-methoxypsoralen | |
| DE69805202D1 (de) | Verwendung von benzhydrylsulfinylderivaten zur behandlung der schläfigkeit medikamentösen ursprungs | |
| DE50014190D1 (de) | Verwendung von phthalazin-derivaten zur behandlung neurodegenerativer krankheiten | |
| ES8506082A1 (es) | Procedimiento para la inactivacion de germenes patogenos, capaces de reproducirse | |
| DE69831406D1 (de) | Verwendung von thiazolidinedion-derivaten zur behandlung des polyzystischen ovarien syndroms und des schwangerschaftsdiabetes | |
| NO954667D0 (no) | Fremgangsmåte til deteksjon av Ki-ras mutasjoner | |
| Adams | Regeneration and the kinetics of peroxidase inactivation | |
| DE69432055D1 (de) | Verwendung von einem mittel, das tyrosinphosphorylierung moduliert, zur modulation der durchlässigkeit einer physiologischen sperrschicht | |
| DE69429299D1 (de) | Verwendung von Tachykinin-Antagonisten zur Behandlung von Erbrechen | |
| WO1997040072A3 (en) | Adam proteins and uses thereof | |
| DE60116642D1 (de) | Verbindungen mit cytochrom p450ra1 hemmenden aktivität | |
| ATE273712T1 (de) | Methode zur inaktivierung von proteinen der ras- unterfamilie und verbindungen dafuer | |
| ATE106250T1 (de) | Verwendung von antikörper-antigen-wechselwirkung zum schutz oder modulation der biologischen aktivität. | |
| DK131284A (da) | Fremgangsmaade til inaktivering af stoffer, der foraarsager uforenelighedsreaktioner | |
| DE69936779D1 (de) | Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen | |
| RU94024337A (ru) | Антиметастатическое средство | |
| ATA119394A (de) | Verwendung von humanem protein c zur verhinderung und behandlung von thrombozytenablagerungen | |
| Bowen et al. | Evidence that polyoma polypeptide VP1 is a serine protease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0877622 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |